FDA approved Enhertu for two new indications in HER2-positive breast cancer patients in neoadjuvant and adjuvant settings.
What this means
Enhertu is a breast cancer treatment that combines a HER2-targeting antibody with a cell-killing drug, delivering the payload directly to tumors. FDA expanded its approval to include use before and after surgery for HER2-positive breast cancer patients. This decision gives doctors a new way to attack aggressive tumors earlier in treatment, potentially improving long-term outcomes for more patients.
